ANAVEX LIFE SCIENCES CORP. 10-Q

ITEM 5. OTHER INFORMATION Insider Trading Plans None of our directors or Section 16 officers informed us of the adoption , modification or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (in each case, as defined in Item 408(a) of Regulation S-K) during the three-month period ended March 31, 2026. 40 ITEM 6. EXHIBITS Exhibit Number Description 3.1 Articles of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to our Annual Report on Form 10-K for the year ended September 30, 2021 filed on November 24, 2021) 3.2 Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on April 14, 2023) 31.1* Certification of Terrie Kellmeyer, PhD. 31.2* Certification of Sandra Boenisch 32.1** Certification of Terrie Kellmeyer, PhD and Sandra Boenisch. 101.INS* XBRL INSTANCE DOCUMENT 101.SCH* XBRL TAXONOMY EXTENSION SCHEMA 101.CAL* XBRL TAXONOMY EXTENSION CALCULATION LINKBASE 101.DEF* XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 101.LAB* XBRL TAXONOMY EXTENSION LABEL LINKBASE 101.PRE* XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE * Filed herewith. ** Furnished herewith. 41 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ANAVEX LIFE SCIENCES CORP. /s/Terrie Kellmeyer, PhD Terrie Kellmeyer, PhD Interim Chief Executive Officer (Principal Executive Officer) Date: August 28, 2026 /s/Sandra Boenisch Sandra Boenisch, CPA, CGA Principal Financial Officer (Principal Financial and Accounting Officer) Date: August 28, 2026 42